Introduction Traditional xenograft models provide valuable insights into tumor biology and therapeutic efficacy but are fundamentally limited in their ability to evaluate immunotherapies. Since immunodeficient murine hosts lack functional adaptive
Introduction Intratumoral heterogeneity is a defining feature of human cancers and a primary driver of therapeutic resistance. Conventional in vitro models fail to capture the dynamic interplay between co-existing subclones,
Introduction Patient-Derived Xenografts (PDX) represent one of the most translationally relevant in vivo cancer models available to preclinical research. By directly implanting tumor fragments harvested from patients into immunodeficient mice,
Introduction Xenograft models are indispensable tools in oncology research, providing a physiologically relevant in vivo platform to study tumor biology, evaluate therapeutic responses, and bridge the translational gap between preclinical
Plymouth Meeting, PA – August 2025 – Cancer remains one of the greatest health burdens worldwide. Preclinical models are indispensable for developing therapies that can effectively translate from the laboratory